Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details)

v3.24.3
Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units - $ / shares
 3 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Awards Outstanding    
Awards Outstanding, Outstanding beginning balance 61,317 [1] 63,587
Awards Outstanding, Shares Granted (as deemed reinvestment of cash dividend equivalents) 52 285
Awards, Outstanding, Vested & delivered   (6,439)
Awards, Outstanding, Vested & deferred [2] (40) (205)
Awards Outstanding, Outstanding ending balance 61,329 [1] 57,228
Awards Outstanding, Vested but subject to deferred settlement [2] 41,987 29,575
Awards Outstanding, Vested and nonvested outstanding 103,316 [1] 86,803
Weighted-Average Fair Value per Unit at Grant Date    
Weighted-Average Fair Value per Unit at Grant Date, Outstanding beginning balance $ 30.61 [1] $ 32.37
Weighted-Average Fair Value per Unit at Grant Date, Shares granted (as deemed reinvestment of cash dividend equivalents) [3] 0 0
Weighted-Average Fair Value per Unit at Grant Date, Vested & delivered   31.06
Weighted-Average Fair Value per Unit at Grant Date, Vested & deferred [2],[3] 0 0
Weighted-Average Fair Value per Unit at Grant Date, Outstanding ending balance 30.61 [1] 32.48
Weighted-Average Fair Value per Unit at Grant Date, Vested but subject to deferred settlement [2] 26.03 24.33
Weighted-Average Fair Value per Unit at Grant Date, Vested and nonvested outstanding $ 28.75 [1] $ 29.7
[1] Includes 6,265 RSUs that vest based on continuous employment and achievement of non-market performance goals through June 30, 2025, and 2026.
[2] Certain RSU holders elected to defer settlement of the RSUs to a specified date. The DSU holder is contractually obligated to defer settlement of the DSUs to a specified date following the holder’s termination of service.
[3] These shares were granted upon deemed reinvestment of dividend equivalents, in accordance with mandatory terms of the award agreement. The measured fair value of the original award fully valued the participant’s right to deemed reinvestment of dividend equivalents, and therefore this grant resulted in no incremental compensation expense, which is reflected in the table as zero fair value for the shares.